WheezingNCT05684848
Evaluate the Effect of Nasal Spray in the Prevention of RTI in Children With Pre-school Wheezing
A study testing Resveratrol + CMG and Isotonic solution in people with Wheezing and Recurrent Respiratory Tract Infections, run by Noos S.r.l. at 1 site in Italy.
Trial summary
To determine whether or not preventive administration of resveratrol in the form of a nasal spray is effective in reducing the number of asthma exacerbations typical of preschool wheezing children who develop viral infections. Read more about this study
- Who is it for?
- Ages 3 to 6 yearsHealthy volunteers can take part
- Conditions the study is for
- Wheezing, Recurrent Respiratory Tract Infections
- What is being tested?
- Resveratrol + CMG and Isotonic solution
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 252 participants
- Where
- 1 siteItaly
- Study dates
- 1 Nov 2022to 31 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 6 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Children diagnosed with wheezing
- Patients aged between 3 and 6 years (inclusive) at the time of enrollment of both genders
- Signature of the informed consent
- Availability of a mobile phone capable of installing VIR@PP
Who cannot join
- Inability to adequately understand the Italian language
- Presence of autoimmune pathologies, immunodeficiency, neuromuscular diseases, congenital cardiomyopathies, metabolic diseases
- Presence of other syndromes and genetic pathologies
- Patients on therapy with other drugs (steroids for topical and/or oral use)
- Abnormalities of the nose or other conditions (e.g. severe hypotonia etc…) which make the administration of a nasal spray impossible or unsafe
- Denial of informed consent
- Participation in other clinical studies
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
University of Campania Luigi Vanvitelli
Naples, 80138
Michele Miraglia del Giudice, Prof
Cristiana Indolfi
About this study
Official title: Interventional Pilot Study to Evaluate the Effect of a Resveratrol-based Nasal Spray Associated With Carboxymethylbetaglucan in Isotonic Solution in the Prevention of RTI in Children With Pre-school Wheezing
To determine whether or not preventive administration of resveratrol in the form of a nasal spray is effective in reducing the number of asthma exacerbations typical of preschool wheezing children who develop viral infections.
Read the detailed description
The surface of the mucous membranes represents the first gateway for many viral agents including respiratory and intestinal ones which have the greatest epidemiological value. Viruses cause damage to these epithelia and can favor bacterial superinfection as well as complications of already existing pathologies; it is therefore essential to identify non-toxic substances that can hinder the entry of the virus and consequently its replication.
Both wheezing and viral infections are common in children, especially under the age of five. In fact, it is recorded that around 25% of children within nine months of age and 50% of children within six years of age have at least one episode of wheezing. Wheezing in young children can have a different etiology: it can be due to an underlying disease such as airway malformation, internal or external airway narrowing, and cystic fibrosis, or it can occur without an underlying disease.
In the latter case, the viral infection represents one of the main causes of wheezing especially in children under five/six years of age. However, not all viral infections cause wheezing.Numerous studies have confirmed a correlation between viral infections and asthma exacerbations in both adults and children. Furthermore, new evidence suggests that viral respiratory infections in the early years of life are related to the medium- and long-term development of asthma There is ample clinical evidence demonstrating a link between early viral infections (especially RV and RSV) and the onset of asthma exacerbations.
In addition to the viruses mentioned above, enteroviruses, bocaviruses, parainfluenza viruses, coronaviruses, metapneumoviruses, influenza viruses and adenoviruses also seem to be implicated.
RSV (respiratory syncytial virus) is the most common cause of bronchiolitis in the first year of life, causes hospitalization and typically circulates in temperate climates from November to April with peaks in the winter months
Although RSV has long been identified as the leading cause of childhood bronchiolitis, the use of molecular techniques, such as PCR, has also identified rhinovirus as a causative agent of asthma exacerbations. Rhinovirus, which circulates year-round with peaks during the fall and spring, as well as being a cause of upper respiratory tract infections, has been shown in some clinical investigations to infect the lower airways, to be associated with childhood bronchiolitis and become a dominant pathogen in wheezing disease as children get older.
In the search for new therapeutic and prevention alternatives that can be considered a valid contribution to reduce the effects of viral infection, the focus has been on effective and early treatments to help prevent the spread of the virus or to neutralize viruses at an early stage when they are lodged in the upper respiratory tract and therefore in the nose, since this is the probable and first route of entry for viruses and therefore for infections.
A nasal spray based on resveratol and carboxymethylbetaglucan (Linfovir® plus nasal spray) was therefore considered, which could be useful in hindering the entry of pathogens (viruses and bacteria) into the nasal cavities thanks to the mechanical action of the washing which goes to counter the engraftment and the consequent easier proliferation of the virus. Furthermore, the product contains resveratrol, a substance of natural origin, produced by various plants in response to stress or injury induced by microorganisms or environmental hazards which protects fruit and vegetables from fungal infections. This plant extract has been widely recognized as having antioxidant properties capable of counteracting the inflammatory stages associated with pathologies of the rhinosinusal tract. Patients infected with respiratory viruses, in fact, show an increased inflammatory state, with high levels of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)α, interleukin IL-6, IL-8 and interferons, in the nasopharyngeal fluids and in plasma. Additionally, in severe viral infections, reactive oxygen species (ROS) produced by inflammatory cells, such as polymorphonuclear cells and neutrophils, recruited to the site of inflammation lead to lung damage.
On the basis of these assumptions, an interventional, randomized, multicenter and controlled clinical study was designed to evaluate whether the spray solution, used to hydrate and clean the nasal mucous membranes at a dosage of 2 sprays per nostril, 2 times a day (in prevention) and 2 sprays per nostril, 4 times a day (in the acute phase), is safe and effective in preventing and treating viral infections typical of the autumn/winter season in preschool wheezing children particularly prone to infections and asthma exacerbations. Thanks to the mechanical effect of washing and through the antioxidant and anti-inflammatory efficacy of resveratrol, amply demonstrated in vitro, the Investigators will evaluate, in the present study, whether the topical administration of resveratrol at the level of the nasal district, in the form of a nasal spray, is able to reduce the number of days in which preschool children present symptoms attributable to respiratory infections.
- Conditions
- Wheezing, Recurrent Respiratory Tract Infections
- Being tested
- Resveratrol + CMG, Isotonic solution
- Keywords
- RRI, Wheezing, Medical Device, Resveratrol
- Medical subject headings
- Respiratory Sounds, Respiratory Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resveratrol + CMGDevice
As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
Isotonic solutionDevice
As prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day.
| Study group | Role | What they receive |
|---|---|---|
| Resveratrol + CMG | Active comparator | Medical device: nasal spray based on resveratrol associated with carboxymethylbetaglucan in isotonic solution Receives: Device: Resveratrol + CMG |
| Isotonic solution | Placebo comparator | Medical Device with isotonic solution Receives: Device: Isotonic solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of the number of days with respiratory symptoms compared to placebo
To determine whether taking resveratrol in the form of a nasal spray changes the number of days with respiratory symptoms compared to placebo.
Measured: 3 months
Secondary outcomes (1)
In case of exacerbations, verify the change in the number of respiratory exacerbations and their duration of the group treated with resveratrol in the form of nasal spray vs the control group.
In case of exacerbations, verify the change in the number of respiratory exacerbations and their duration of the group treated with resveratrol in the form of nasal spray vs the control group. The number of days of use of antipyretics, oral corticosteroids and salbutamol will also be evaluated in the two groups.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2023
- Study start1 Nov 2022
- Primary completion31 Dec 2023 (estimated)
- Study completion31 May 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for WheezingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 252 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Noos S.r.l.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Michele Miraglia del Giudice, Prof., Principal investigator, University of Campania Luigi Vanvitelli - Naples; Italy 80138
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05684848
- Sponsor's protocol ID
- LFV_PRE
- Status last verified
- Jan 2023
- First submitted
- 5 Jan 2023
- Last updated
- 17 Jan 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Interventional Pilot Study to Evaluate the Effect of a Resveratrol-based Nasal Spray Associated With Carboxymethylbetaglucan in Isotonic Solution in the Prevention of RTI in Children With Pre-school Wheezing
- ClinicalTrials.gov ID
- NCT05684848
- Acronym / sponsor ID
- LFV_PRE
- Conditions
- Wheezing, Recurrent Respiratory Tract Infections
- Keywords
- RRI, Wheezing, Medical Device, Resveratrol
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 252 participants (estimated)
- Lead sponsor
- Noos S.r.l.Industry (pharma, biotech, devices)
- Study start
- 1 Nov 2022 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 May 2024 (estimated)
- First posted
- 13 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine whether or not preventive administration of resveratrol in the form of a nasal spray is effective in reducing the number of asthma exacerbations typical of preschool wheezing children who develop viral infections.
Detailed description
The surface of the mucous membranes represents the first gateway for many viral agents including respiratory and intestinal ones which have the greatest epidemiological value. Viruses cause damage to these epithelia and can favor bacterial superinfection as well as complications of already existing pathologies; it is therefore essential to identify non-toxic substances that can hinder the entry of the virus and consequently its replication.
Both wheezing and viral infections are common in children, especially under the age of five. In fact, it is recorded that around 25% of children within nine months of age and 50% of children within six years of age have at least one episode of wheezing. Wheezing in young children can have a different etiology: it can be due to an underlying disease such as airway malformation, internal or external airway narrowing, and cystic fibrosis, or it can occur without an underlying disease.
In the latter case, the viral infection represents one of the main causes of wheezing especially in children under five/six years of age. However, not all viral infections cause wheezing.Numerous studies have confirmed a correlation between viral infections and asthma exacerbations in both adults and children. Furthermore, new evidence suggests that viral respiratory infections in the early years of life are related to the medium- and long-term development of asthma There is ample clinical evidence demonstrating a link between early viral infections (especially RV and RSV) and the onset of asthma exacerbations.
In addition to the viruses mentioned above, enteroviruses, bocaviruses, parainfluenza viruses, coronaviruses, metapneumoviruses, influenza viruses and adenoviruses also seem to be implicated.
RSV (respiratory syncytial virus) is the most common cause of bronchiolitis in the first year of life, causes hospitalization and typically circulates in temperate climates from November to April with peaks in the winter months
Although RSV has long been identified as the leading cause of childhood bronchiolitis, the use of molecular techniques, such as PCR, has also identified rhinovirus as a causative agent of asthma exacerbations. Rhinovirus, which circulates year-round with peaks during the fall and spring, as well as being a cause of upper respiratory tract infections, has been shown in some clinical investigations to infect the lower airways, to be associated with childhood bronchiolitis and become a dominant pathogen in wheezing disease as children get older.
In the search for new therapeutic and prevention alternatives that can be considered a valid contribution to reduce the effects of viral infection, the focus has been on effective and early treatments to help prevent the spread of the virus or to neutralize viruses at an early stage when they are lodged in the upper respiratory tract and therefore in the nose, since this is the probable and first route of entry for viruses and therefore for infections.
A nasal spray based on resveratol and carboxymethylbetaglucan (Linfovir® plus nasal spray) was therefore considered, which could be useful in hindering the entry of pathogens (viruses and bacteria) into the nasal cavities thanks to the mechanical action of the washing which goes to counter the engraftment and the consequent easier proliferation of the virus. Furthermore, the product contains resveratrol, a substance of natural origin, produced by various plants in response to stress or injury induced by microorganisms or environmental hazards which protects fruit and vegetables from fungal infections. This plant extract has been widely recognized as having antioxidant properties capable of counteracting the inflammatory stages associated with pathologies of the rhinosinusal tract. Patients infected with respiratory viruses, in fact, show an increased inflammatory state, with high levels of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)α, interleukin IL-6, IL-8 and interferons, in the nasopharyngeal fluids and in plasma. Additionally, in severe viral infections, reactive oxygen species (ROS) produced by inflammatory cells, such as polymorphonuclear cells and neutrophils, recruited to the site of inflammation lead to lung damage.
On the basis of these assumptions, an interventional, randomized, multicenter and controlled clinical study was designed to evaluate whether the spray solution, used to hydrate and clean the nasal mucous membranes at a dosage of 2 sprays per nostril, 2 times a day (in prevention) and 2 sprays per nostril, 4 times a day (in the acute phase), is safe and effective in preventing and treating viral infections typical of the autumn/winter season in preschool wheezing children particularly prone to infections and asthma exacerbations. Thanks to the mechanical effect of washing and through the antioxidant and anti-inflammatory efficacy of resveratrol, amply demonstrated in vitro, the Investigators will evaluate, in the present study, whether the topical administration of resveratrol at the level of the nasal district, in the form of a nasal spray, is able to reduce the number of days in which preschool children present symptoms attributable to respiratory infections.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Resveratrol + CMG | Active comparator | Device: Resveratrol + CMGMedical device: nasal spray based on resveratrol associated with carboxymethylbetaglucan in isotonic solution |
| Isotonic solution | Placebo comparator | Device: Isotonic solutionMedical Device with isotonic solution |
Who may qualify
- Ages
- 3 to 6 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Children diagnosed with wheezing
Key exclusion criteria (7 listed)
- Inability to adequately understand the Italian language
- Presence of autoimmune pathologies, immunodeficiency, neuromuscular diseases, congenital cardiomyopathies, metabolic diseases
- Presence of other syndromes and genetic pathologies
- Patients on therapy with other drugs (steroids for topical and/or oral use)
- Abnormalities of the nose or other conditions (e.g. severe hypotonia etc…) which make the administration of a nasal spray impossible or unsafe
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resveratrol + CMGAs prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day. | Device | Resveratrol + CMG |
| Isotonic solutionAs prevention (resveratrol or its placebo) 2 puffs per nostril 2 times a day (morning and evening) for a period of 3 months. If during the preventive administration of the spray the first symptoms of a viral infection should appear, the parent should increase the dosage of the nasal spray to 2 puffs per nostril 4 times a day. | Device | Isotonic solution |
Primary outcome
Change of the number of days with respiratory symptoms compared to placebo
Time frame: 3 months
To determine whether taking resveratrol in the form of a nasal spray changes the number of days with respiratory symptoms compared to placebo.
1 secondary outcome
In case of exacerbations, verify the change in the number of respiratory exacerbations and their duration of the group treated with resveratrol in the form of nasal spray vs the control group.
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2023.
- Individual participant dataSharing planned: No
Related trials for Wheezing
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Not yet recruitingPhase 4
Prevent Wheeze Trial
Lower Respiratory Tract Infection (LRTI), Recurrent Wheezing
RecruitingPhase 3
Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.
Wheezing, LRTI
RecruitingObservational study
N-WATCH: Nottingham Wheeze Assessment in Tidal Children
Asthma in Children
Not yet recruitingPhase 1/2
Genes, Soy Isoflavones, and Virus
Wheezing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michele Miraglia del Giudice, Prof. principal investigator
University of Campania Luigi Vanvitelli - Naples; Italy 80138
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resveratrol + CMG and Isotonic solution in people with Wheezing and Recurrent Respiratory Tract Infections, run by Noos S.r.l. at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 17 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Michele Miraglia del Giudice, Prof (0815665470, Michele.MIRAGLIADELGIUDICE@unina2.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of the number of days with respiratory symptoms compared to placebo (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2023.